Zavabresib clinical trials
Also written PLX2853.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses zavabresib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PLX2853
- 4
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Opna Bio LLC (4) · Alliance for Clinical Trials in Oncology (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses zavabresib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedPhase 1/2Opna Bio LLCNCT04556617Written as PLX2853 20 mg
- PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian CancerTerminatedPhase 1/2Opna Bio LLCNCT04493619Written as PLX2853
- Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal MelanomaWithdrawnPhase 1/2Alliance for Clinical Trials in OncologyNCT05677373Written as BRD4 Inhibitor PLX2853
- A Study of PLX2853 in Advanced Malignancies.CompletedPhase 1Opna Bio LLCNCT03297424Written as PLX2853
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedPhase 1Opna Bio LLCNCT03787498Written as PLX2853
Codes
What other systems call zavabresib · ClinicalTrials.gg INT018398
- UNII (FDA) WY57S8PGY9ZAVABRESIBConfirmed FDA, Wikidata
- Wikidata Q140529369zavabresibConfirmed FDA, Wikidata
- NCI Thesaurus C224806ZavabresibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WY57S8PGY9 | ZAVABRESIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529369 | zavabresib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C224806 | Zavabresib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.